Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

Launched by DAPING HOSPITAL AND THE RESEARCH INSTITUTE OF SURGERY OF THE THIRD MILITARY MEDICAL UNIVERSITY · May 28, 2024

Keywords

ClinConnect Summary

Although Osimertinib has become the standard first-line treatment choice for EGFRm advanced NSCLC, a subset of patients still do not benefit from first-line Osimertinib treatment. Some patients even experience disease progression at the initial stages of Osimertinib treatment. As early as 2010 and 2016, studies published in J Clin Oncol and Onco Targets Ther noted that approximately 10-30% of patients either do not respond to initial EGFR TKI treatment or experience disease control for less than 3 months despite carrying EGFR mutations (PMID: 19949011, 27382309). Furthermore, the FLAURA stu...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18 to 79 years.
• • 2. Locally advanced (stage IIIB) or metastatic (stage IV) EGFR-mutant NSCLC.
• • 3. Harboring an EGFR sensitizing mutation (Exon 19 deletion or L858R).
• • 4. Received at least two cycles of first-line osimertinib treatment, with a best response of stable disease or slow progression.
• • 5. Life expectancy greater than 3 months.
• 6. At least one measurable tumor lesion meeting the following criteria:
• • 1.No prior radiation therapy; 2.Measurable by chest CT or PET-CT, with a longest diameter ≥ 10 mm at baseline (short axis ≥ 15 mm for lymph nodes); 3.Amenable to accurate repeated measurements.
• Exclusion Criteria:
• • 1. Currently receiving or planning to receive other anti-cancer therapies.
• • 2. Having contraindications to osimertinib or etoposide.
• • 3. Harboring known targetable osimertinib resistance mechanisms.